secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001558370-25-010393
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne Q4 GAAP EPS -$0.11, adjusted EPS $0.53; organic revenue +3%; announces Exosome divestiture
--------------------------------------------------------------------------------

- GAAP EPS loss of $0.11 vs $0.25 profit a year ago; adjusted EPS $0.53 vs $0.49.
- Q4 organic revenue up 3% (reported 4%) to $317.0M; full year organic +5% to $1.2B.
- Protein Sciences segment organic growth 4% (reported 6%) in Q4.
- Announced divestiture of Exosome Diagnostics business including ExoDx Prostate test.
- Board declared $0.08/share quarterly dividend, payable Aug 29, record Aug 18.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000155837025010393/0001558370-25-010393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000155837025010393/tech-20250806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer